Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Field Cancerization for Reduction in Tumor Burden - A Prospective Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria~1. Subjects with ages between 18 and 85 years, male or female.~2. Subjects with at least 4 clinically diagnosed actinic keratoses (AKs) per treatment site ( up to 200 sq cm), excluding the face and neck~3. Subjects with history of at least 1 non-melanoma skin cancer within the past year~4. Willingness to participate in the study~5. Informed consent agreement signed by the subject~6. Willingness to follow the treatment schedule and post treatment care requirements~7. Willingness to not use topical or systemic (oral) TREATMENT medications including imiquimod, 5-Fluorouracil, photodynamic therapy, during the treatment period.~8. Has not had treatment for AKs in the treatment area for 4 weeks prior to enrollment~Exclusion criteria~1. Subjects with active skin cancer in the treatment area. Once the non-melanoma skin cancer has been treated, the subject can be immediately enrolled.~2. Infection of the area to be treated~3. An open wound in the area to be treated~4. Presence of suntan in the area to be treated, or active tanning during the study~5. Subjects who have taken medication known to induce photosensitivity in the previous 3 months~6. The patient has any contraindication to use of the carbon dioxide laser, including but not limited to, intake of isotretinoin in past 12 months; patients with reduced adnexal structures (eg, scleroderma, irradiation or burns); patients with history of vitiligo or psoriasis (risk of Koebnerization); history of keloids/hypertrophic scarring.~7. Subject is unable to comply with treatment, home care or follow-up visits~8. Subject is pregnant or breast feeding~9. Prior use of topical retinoids, 5 fluorouracil, or imiquimod in treated areas within one month of initial treatment~10. Prior skin treatment with laser or other devices in the treated area within two months of initial treatment or during the course of the study;~11. Adverse reactions to compounds of any external agent (e.g., gels, lotions or anesthetic creams) required for use in the study, if no alternative to the said agent exists;~12. Concurrent inflammatory skin conditions, including, but not limited to, eczema, contact dermatitis of any severity;~13. Active Herpes Simplex at the time of treatment;~14. Multiple dysplastic nevi in area to be treated;~15. Having a bleeding disorder or taking anticoagulation medications, including heavy use of aspirin, in a manner which does not allow for a minimum 10 day washout period prior to each treatment (as per the patient's physician discretion);~16. Significant concurrent illness, such as uncontrolled diabetes, (i.e., any disease state that in the opinion of the Investigator would interfere with the anesthesia, treatment, or healing process);~17. Mentally incompetent, prisoner or evidence of active substance or alcohol abuse;~18. Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or study personnel) to treat the subject as part of this research study;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Ultrapulse laser alone (Type: ACTIVE_COMPARATOR): None
- Ultrapulse laser plus Cellutome Harvesting system (Type: ACTIVE_COMPARATOR): None
- Control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues